MW 303.13 Da, Purity >99%. Ethacrynic acid, Glutathione S-transferase (GST) inhibitor. Achieve your results faster with highly validated, pure and trusted compounds.
Images
Publications
Filter by
- Cancers 13:2021SIRT3 and Metabolic Reprogramming Mediate the Antiproliferative Effects of Whey in Human Colon Cancer Cells.Applications:Unspecified applicationReactive species:Unspecified reactive speciesNunzia D'Onofrio,Elisa Martino,Anna Balestrieri,Luigi Mele,Gianluca Neglia,Maria Luisa Balestrieri,Giuseppe CampanilePubMed 34680344
Key facts
- CAS number
- 58-54-8
- Purity
- > 99%
- Form
- Solid
- Molecular weight
- 303.13 Da
- Molecular formula
- C13H12Cl2O4
- PubChem identifier
- 3278
- Nature
- Synthetic
Target data
Alternative names
(R)-limonene 6-monooxygenase, (S)-limonene 6-monooxygenase, (S)-limonene 7-monooxygenase, CP2C9_HUMAN, CPC9, CYP2C, CYP2C10, CYPIIC9, Cytochrome P-450MP, Cytochrome P450 2C9, Cytochrome P450 MP-4, Cytochrome P450 MP-8, Cytochrome P450 PB-1, Cytochrome P450, family 2, subfamily C, polypeptide 9, MGC149605, MGC88320, Microsomal monooxygenase, NF-E2-related factor 2, NF2L2_HUMAN, NRF2, Nfe2l2, Nuclear factor, Nuclear factor (erythroid derived 2) like 2, Nuclear factor erythroid 2-related factor 2, Nuclear factor erythroid derived 2 like 2, OTTHUMP00000020135, P450 MP, P450 PB 1, P450IIC9, S-mephenytoin 4-hydroxylase, Xenobiotic monooxygenase, cytochrome P-450 S-mephenytoin 4-hydroxylase, erythroid derived 2, flavoprotein-linked monooxygenase, like 2, nuclear factor erythroid 2 like 2
Recommended products
MW 303.13 Da, Purity >99%. Ethacrynic acid, Glutathione S-transferase (GST) inhibitor. Achieve your results faster with highly validated, pure and trusted compounds.
Key facts
- CAS number
- 58-54-8
- Purity
- > 99%
- Form
- Solid
- Molecular weight
- 303.13 Da
- Molecular formula
- C13H12Cl2O4
- PubChem identifier
- 3278
- Nature
- Synthetic
- Solubility
Soluble in ethanol to 100 mM.
Soluble in DMSO to 100mM.
- Biochemical name
- Ethacrynic acid
- Canonical SMILES
- CCC(=C)C(=O)C1=C(C(=C(C=C1)OCC(=O)O)Cl)Cl
- InChI
- InChI=1S/C13H12Cl2O4/c1-3-7(2)13(18)8-4-5-9(12(15)11(8)14)19-6-10(16)17/h4-5H,2-3,6H2,1H3,(H,16,17)
- InChIKey
- AVOLMBLBETYQHX-UHFFFAOYSA-N
- IUPAC name
- 2-[2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetic acid
Storage
- Shipped at conditions
- Ambient - Can Ship with Ice
- Appropriate short-term storage conditions
- Ambient
- Appropriate long-term storage conditions
- Ambient
- Storage information
- The product can be stored for up to 12 months
Supplementary info
- This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
CYP2C9 also known as Cytochrome P450 2C9 is an enzyme that plays a significant role in drug metabolism. It is a member of the cytochrome P450 superfamily with a molecular mass of approximately 55 kDa. The enzyme is predominantly found in the liver where it contributes to the oxidation of various substrates including drugs cholesterol and other lipids. It is an important target in pharmacogenomics due to its influence on drug clearance and interaction.
- Biological function summary
CYP2C9 participates in the phase I metabolism of xenobiotics and endogenous compounds. It is not part of a larger complex but works closely with other enzymes to sustain metabolic processes. CYP2C9 converts lipophilic molecules into more hydrophilic forms which facilitates their subsequent conjugation and elimination. Its activity affects the pharmacokinetics and pharmacodynamics of nonsteroidal anti-inflammatory drugs (NSAIDs) and oral anticoagulants.
- Pathways
CYP2C9 is essential in the arachidonic acid metabolism and steroid hormone biosynthesis pathways. In these pathways it interacts with other cytochrome P450 enzymes like CYP3A4 to metabolize drugs and steroids. The synergy between CYP2C9 and related enzymes ensures efficient metabolic clearance of drugs and bioactive lipids although it can also lead to drug interactions if multiple drugs are metabolized by the same enzyme.
- Associated diseases and disorders
CYP2C9 polymorphisms have been linked to altered drug metabolism particularly affecting therapeutic outcomes in cardiovascular conditions and epilepsy. Variants of CYP2C9 can lead to increased or decreased metabolism of warfarin commonly used in cardiovascular disease management. Disorders related to CYP2C9 activity often involve impaired clearance of therapeutic agents and are also seen in conjunction with variations in other metabolic enzymes such as GST (glutathione S-transferase).
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
1 product image
Chemical Structure - Ethacrynic acid, Glutathione S-transferase (GST) inhibitor (ab141399)
2D chemical structure image of ab141399, Ethacrynic acid, Glutathione S-transferase (GST) inhibitor
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com